These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
64. [Elevated expression of matrix metalloproteinase-9, and fibronectin concentration in recurrent epithelial ovarian cancer]. Demeter A; Szirmai K; Oláh J; Papp Z; Jeney A Orv Hetil; 2004 Aug; 145(31):1617-24. PubMed ID: 15384859 [TBL] [Abstract][Full Text] [Related]
65. Is there a role for urokinase-type plasminogen activator inhibitors as maintenance therapy in patients with ovarian cancer? van Dam PA; Coelho A; Rolfo C Eur J Surg Oncol; 2017 Feb; 43(2):252-257. PubMed ID: 27345498 [TBL] [Abstract][Full Text] [Related]
66. Expression of membrane type 1 matrix metalloproteinase (MMP-14) in epithelial ovarian cancer: high level expression in clear cell carcinoma. Adley BP; Gleason KJ; Yang XJ; Stack MS Gynecol Oncol; 2009 Feb; 112(2):319-24. PubMed ID: 18976802 [TBL] [Abstract][Full Text] [Related]
67. Nanog is highly expressed in ovarian serous cystadenocarcinoma and correlated with clinical stage and pathological grade. Pan Y; Jiao J; Zhou C; Cheng Q; Hu Y; Chen H Pathobiology; 2010; 77(6):283-8. PubMed ID: 21266826 [TBL] [Abstract][Full Text] [Related]
68. ACE inhibition reduces activity of the plasminogen/plasmin and MMP systems in the brain of spontaneous hypertensive stroke-prone rats. Liebetrau M; Burggraf D; Wunderlich N; Jäger G; Linz W; Hamann GF Neurosci Lett; 2005 Mar; 376(3):205-9. PubMed ID: 15721222 [TBL] [Abstract][Full Text] [Related]
69. Coordinate expression of matrix-degrading proteinases and their activators and inhibitors in bovine skeletal muscle. Balcerzak D; Querengesser L; Dixon WT; Baracos VE J Anim Sci; 2001 Jan; 79(1):94-107. PubMed ID: 11204721 [TBL] [Abstract][Full Text] [Related]
70. Down-regulation of urokinase plasminogen activator and matrix metalloproteinases and up-regulation of their inhibitors by a novel nutrient mixture in human prostate cancer cell lines PC-3 and DU-145. Roomi MW; Kalinovsky T; Rath M; Niedzwiecki A Oncol Rep; 2011 Dec; 26(6):1407-13. PubMed ID: 21874261 [TBL] [Abstract][Full Text] [Related]
71. Combined overexpression of urokinase, urokinase receptor, and plasminogen activator inhibitor-1 is associated with breast cancer progression: an immunohistochemical comparison of normal, benign, and malignant breast tissues. Costantini V; Sidoni A; Deveglia R; Cazzato OA; Bellezza G; Ferri I; Bucciarelli E; Nenci GG Cancer; 1996 Mar; 77(6):1079-88. PubMed ID: 8635127 [TBL] [Abstract][Full Text] [Related]
72. Progressive loss of selenium-binding protein 1 expression correlates with increasing epithelial proliferation and papillary complexity in ovarian serous borderline tumor and low-grade serous carcinoma. Zhang C; Wang YE; Zhang P; Liu F; Sung CJ; Steinhoff MM; Quddus MR; Lawrence WD Hum Pathol; 2010 Feb; 41(2):255-61. PubMed ID: 19896693 [TBL] [Abstract][Full Text] [Related]
73. Macrophage colony-stimulating factor mediates invasion of ovarian cancer cells through urokinase. Chambers SK; Wang Y; Gertz RE; Kacinski BM Cancer Res; 1995 Apr; 55(7):1578-85. PubMed ID: 7882368 [TBL] [Abstract][Full Text] [Related]
74. Macrophages of M1 phenotype have properties that influence lung cancer cell progression. Hedbrant A; Wijkander J; Seidal T; Delbro D; Erlandsson A Tumour Biol; 2015 Nov; 36(11):8715-25. PubMed ID: 26050228 [TBL] [Abstract][Full Text] [Related]
75. [Expression of KiSS-1, matrix metalloproteinase-9, nuclear factor-kappaBp65 in ovarian tumour]. Gao GL; Liu LD; Zou XS; Chen WX Zhonghua Fu Chan Ke Za Zhi; 2007 Jan; 42(1):34-8. PubMed ID: 17331419 [TBL] [Abstract][Full Text] [Related]
76. Critical involvement of ILK in TGFbeta1-stimulated invasion/migration of human ovarian cancer cells is associated with urokinase plasminogen activator system. Lin SW; Ke FC; Hsiao PW; Lee PP; Lee MT; Hwang JJ Exp Cell Res; 2007 Feb; 313(3):602-13. PubMed ID: 17187779 [TBL] [Abstract][Full Text] [Related]
77. Cancer Stem Cell-Related Marker NANOG Expression in Ovarian Serous Tumors: A Clinicopathological Study of 159 Cases. Kenda Šuster N; Frković Grazio S; Virant-Klun I; Verdenik I; Smrkolj Š Int J Gynecol Cancer; 2017 Nov; 27(9):2006-2013. PubMed ID: 28906309 [TBL] [Abstract][Full Text] [Related]
78. The clinical role of phospholipase A2 isoforms in advanced-stage ovarian carcinoma. Gorovetz M; Baekelandt M; Berner A; Trope' CG; Davidson B; Reich R Gynecol Oncol; 2006 Dec; 103(3):831-40. PubMed ID: 16919315 [TBL] [Abstract][Full Text] [Related]
79. [Matrix metalloproteinases 2 and 9, their endogenous regulators, and angiotensin-converting enzyme in cervical squamous cell carcinoma]. Timoshenko OS; Kugaevskaya EV; Gureeva TA; Zavalishina LE; Andreeva YY; Solovуeva NI Arkh Patol; 2015; 77(5):31-35. PubMed ID: 26978018 [TBL] [Abstract][Full Text] [Related]
80. Melatonin inhibits postischemic matrix metalloproteinase-9 (MMP-9) activation via dual modulation of plasminogen/plasmin system and endogenous MMP inhibitor in mice subjected to transient focal cerebral ischemia. Tai SH; Chen HY; Lee EJ; Chen TY; Lin HW; Hung YC; Huang SY; Chen YH; Lee WT; Wu TS J Pineal Res; 2010 Nov; 49(4):332-41. PubMed ID: 20663046 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]